Newer generation antidepressants for depressive disorders in children and adolescents

Cochrane Database of Systematic Reviews

Volumn 2021, Issue 9, 2012, Pages

  Hetrick, Sarah E ^a   McKenzie, Joanne E ^b   Cox, Georgina R ^a   Simmons, Magenta B ^a   Merry, Sally N ^c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; FLUOXETINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADOLESCENT; CHILD; DEPRESSION; HUMAN; INDUCTION CHEMOTHERAPY; META ANALYSIS; PSYCHOLOGICAL ASPECT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SUICIDE;

ADOLESCENT; ANTIDEPRESSIVE AGENTS; CHILD; CITALOPRAM; DEPRESSIVE DISORDER; FLUOXETINE; HUMANS; INDUCTION CHEMOTHERAPY; PAROXETINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; SUICIDE;

EID: 84872189355     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD004851.pub3     Document Type: Article

References (238)

1. Almeida-Montes LG, Friederichsen A. Treatment of major depressive disorder with fluoxetine in children and adolescents. A double-blind, placebo-controlled study [Tratamiento del trastorno depresivo mayor con fluoxetina en ninos y adolescentes. Estudio doble ciego, controlado con placebo]. Psiquiatria Biologica 2005;12(5):198-205. x-wiley/crsRef/18709806
2. Berard R, Fong R, Carpenter DJ, Thomason C, Wilkinson C. An international, multicentre, placebo-controlled trial of paroxetine in adolescents with major depressive disorder. Journal of Child and Adolescent Psychopharmacology 2004;16(1-2):59-75. x-wiley/crsRef/18709808
3. GlaxoSmithKline. A double-blind, multicentre placebo controlled study of paroxetine in adolescents with unipolar major depression [Study 377]. www.gsk.com/media/paroxetine.htm (accessed 16 August 2004). x-wiley/crsRef/18709809
4. Medicines and Healthcare products Regulatory Agency (MHRA). Paroxetine Study 2 ID#377. http://medicines.mhra.gov.uk (accessed 20 June 2004). x-wiley/crsRef/18709810
5. Milin R, Simeon J, Spenst W. Double-blind study of paroxetine in adolescents with unipolar major depression. Unpublished manuscript. x-wiley/crsRef/18709811
6. Emslie GJ, Rush AJ, Weinberg WA, Kowatch RA, Carmody T, Mayes TL. Fluoxetine in child and adolescent depression: acute and maintenance treatment. Depression and Anxieety 1998;7:32-9. x-wiley/crsRef/18709813
7. Emslie GJ, Rush AJ, Weinberg WA, Kowatch RA, Hughes CW, Carmody T. A double-blind placebo controlled trial of fluoxetine in depressed children and adolescents. In: Sixth World Congress of Biological Psychiatry, Nice, France. June 22-27. 1997. x-wiley/crsRef/18709814
8. Emslie GJ, Rush R, Weinberg WA, Kowatch WA, Hughes CW, Carmody T et al. A double blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Archives of General Psychiatry 1997;54(11):1031-7. x-wiley/crsRef/18709815
9. Emslie GJ, Weinberg WA, Mayes TL. Treatment of children with antidepressants: focus on selective serotonin reuptake inhibitors. Depression and Anxiety 1998;8(Suppl 1):13-7. x-wiley/crsRef/18709816
10. Hughes CW, Emslie G, Kowatch R, Weinberg W, Rintelmann J, Rush AJ. Clinician, parent, and child prediction of medication or placebo in double-blind depression study. Neuropsychopharmacology 2000;23(5):591-4. x-wiley/crsRef/18709817
11. Kowatch RA, Carmody TJ, Emslie GJ, Rintelmann JW, Hughes CW, Rush AJ. Prediction of response to fluoxetine and placebo in children and adolescents with major depressive disorder: a hypothesis generating study. Journal of Affective Disorders 1999;54:269-76. x-wiley/crsRef/18709818
12. Medicines and Healthcare products Regulatory Agency (MHRA). Fluoxetine Study 1 ID# X065. http://medicines.mhra.gov.uk (assessed 20 June 2004). x-wiley/crsRef/18709819
13. Rintelmann JW, Emslie GJ, Rush AJ, Varghese T, Gullion CM, Kowatch RA et al. The effects of extended evaluation on depressive symptoms in children and adolescents. Journal of Affective Disorders 1996;41:149-56. x-wiley/crsRef/18709820
14. Emslie GJ, Heiligenstein JH, Hoog SL, Judge R, Brown EB, Nilsson M. Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000 Dec 10-14; San Juan, Puerto Rico. 2000:172. x-wiley/crsRef/18709822
15. Emslie GJ, Heiligenstein JH, Wagner KD, Hoog SI, Ernest DE, Brown E et al. Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled randomized clinical trial. Journal of the American Academy of Child and Adolescent Psychiatry 2002;41(10):1205-15. x-wiley/crsRef/18709823
16. Jain S, Carmody TJ, Trivedi MH, Hughes C, Bernstein IH, Morris D et al. A psychometric evaluation of the CDRS and MADRS in assessing depressive symptoms in children. Journal of the American Academy of Child & Adolescent Psychiatry 2007;46(9):1204-12. x-wiley/crsRef/18709824
17. Medicines and Healthcare products Regulatory Agency (MHRA). Fluoxetine Study 2 ID# HCJE. http://medicines.mhra.gov.uk (accessed 20 June 2004). x-wiley/crsRef/18709825
18. Nilsson M, Joliat MJ, Miner CM, Brown EB, Heiligenstein JH. Safety of subchronic treatment with fluoxetine for major depressive disorder in children and adolescents. Journal of Child and Adolescent Psychopharmacology 2004;14(3):412-7. x-wiley/crsRef/18709826
19. Brooks SJ, Krulewicz MA, Kutcher S. The Kutcher Adolescent Depression Scale: assessment of its evaluative properties over the course of an 8-week pediatric pharmacotherapy trial. Journal of Child and Adolescent Psychopharmacology 2003;13(3):227-349. x-wiley/crsRef/18709828
20. Emslie GJ, Wagner KD, Kutcher S, Krulewicz S, Fong R, Carpenter DJ et al. Paroxetine treatment in children and adolescents with major depressive disorder: a randomized, multicentre, double-blind, placebo-controlled trial. Journal of the American Academy of Child and Adolescent Psychiatry 2006;45(6):709-19. x-wiley/crsRef/18709829
21. GlaxoSmithKline. A randomized multicentre, 8-week, double-blind, placebo-controlled flexible dose study to evaluate the efficacy and safety of paroxetine in children and adolescents with major depressive disorder (29060/701). www.gsk.com/media/paroxetine.htm (accessed 16 August 2004). x-wiley/crsRef/18709830
22. Medicines and Healthcare products Regulatory Agency (MHRA). Paroxetine Study 3 ID#701. http://medicines.mhra.gov.uk (accessed 20 June 2004). x-wiley/crsRef/18709831
23. Emslie GJ, Finding RL, Yeung PP, Kunz NR, Li Y, Durn BL. Efficacy and safety of venlafaxine ER in children and adolescents with major depressive disorder (poster presentation). In: Proceedings of the American Psychiatric Association; 2004 May 1-6; New York. 2004. x-wiley/crsRef/18709833
24. Emslie GJ, Findling RL, Yeung PP, Kunz NR, Li Y. Venlafaxine ER for the treatment of pediatric subjects with depression: results of two placebo-controlled trials. Journal of the American Academy of Child and Adolescent Psychiatry 2007;46(4):479-88. x-wiley/crsRef/18709834
25. Emslie GJ, Yeung PR, Kunz NR, Li Y. Long-term efficacy and safety of venlafaxine ER in children and adolescents with major depressive disorder. In: Proceedings of the American Psychiatric Association; 2004 May 1-6; New York. 2004. x-wiley/crsRef/18709835
26. Wyeth. Double-blind, placebo-controlled study of venlafaxine ER in children and adolescents with major depression. (Protocol 0600B1-382-US (Study Period: October 1997 to September 2000)). http://www.clinicalstudyresults.org/documents/company-study_44_0.pdf 2004 (accessed 24 November 2011). x-wiley/crsRef/18709837
27. Wyeth. Double-blind, placebo-controlled study of venlafaxine ER in children and adolescents with major depressive disorder. (Protocol 0600B1-394-US) (Study Period: August 2000 to August 2001). http://www.clinicalstudyresults.org/documents/company-study_2252_0.pdf 2004 (accessed 24 November 2011). x-wiley/crsRef/18709839
28. Emslie GJ, Ventura D, Korotzer A, Tourkodimitris S. Escitalopram in the treatment of adolescent depression: a randomized placebo-controlled multisite trial. Journal of the American Academy of Child and Adolescent Psychiatry 2009;48(7):721-9. x-wiley/crsRef/18709841
29. GlaxoSmithKline. A multi-centre, double-blind, placebo controlled study of paroxetine and imipramine in adolescents with unipolar major depression - acute phase (29060/329). www.gsk.com/media/paroxetine.htm (accessed 16 August 2004). x-wiley/crsRef/18709843
30. Jureidini J, Tonkin A. Paroxetine in major depression. Journal of the American Academy of Child and Adolescent Psychiatry 2003;42(5):514. x-wiley/crsRef/18709844
31. Keller MB, Ryan ND, Birmaher B, Klein RG, Strober M, Wagner KD et al. Paroxetine and imipramine in the treatment of adolescent depression [Abstract NR206]. Proccedings of the 151st Annual Meeting of the American Psychiatric Association: New Research Program and Abstracts; 1998 May 30 - June 4; Toronto, Ontario, Canada 1998:123. x-wiley/crsRef/18709845
32. Keller MB, Ryan ND, Strober M, Klein RG, Kutcher SP, Birmaher B et al. Efficacy of paroxetine in the treatment of adolescent major depression: a randomised controlled trial. Journal of the American Academy of Child and Adolescent Psychiatry 2001;40(7):762-72. x-wiley/crsRef/18709846
33. Medicines and Healthcare products Regulatory Agency (MHRA). Paroxetine Study 1 ID#329. http://medicines.mhra.gov.uk (accessed 20 June 2004). x-wiley/crsRef/18709847
34. Rapporteurs Public Assessment Report for Peadiatric Data in EU Worksharing Procedure: Mirtazapine (Remeron). UK/H/0016/pdWS/001 (http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Paediatric_Regulation/Assessment_Reports/Article_45_work-sharing/Mirtazapine_2010_07_45PaedPAR.pdf) 18 June 2010. x-wiley/crsRef/18709849
35. www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM164066.pdf. x-wiley/crsRef/18709850
36. Organon Pharmaceuricals USA Inc. A multicenter, randomized, double-blind, placebo-controlled, efficacy and safety study of Remeron® in outpatient children and adolescents with major depressive disorder [Studies 1 and 2]. http://www.clinicalstudyresults.org/documents/company-study_51_0.pdf 2001 (accessed 24 November 2011). x-wiley/crsRef/18709852
37. Rapporteurs Public Assessment Report for Peadiatric Data in EU Worksharing Procedure: Mirtazapine (Remeron). UK/H/0016/pdWS/001 (http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Paediatric_Regulation/Assessment_Reports/Article_45_work-sharing/Mirtazapine_2010_07_45PaedPAR.pdf) 18 June 2010. x-wiley/crsRef/18709853
38. www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM164066.pdf. x-wiley/crsRef/18709854
39. Rapporteurs Public Assessment Report for Peadiatric Data in EU Worksharing Procedure: Mirtazapine (Remeron). UK/H/0016/pdWS/001 (http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/Paediatric_Regulation/Assessment_Reports/Article_45_work-sharing/Mirtazapine_2010_07_45PaedPAR.pdf) 18 June 2010. x-wiley/crsRef/18709856
40. www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM164066.pdf. x-wiley/crsRef/18709857
41. GlaxoSmithKline. A randomised, double-blind, placebo controlled, parallel group, flexible dose study to evaluate the efficacy and safety of Paxil® tablets in children and adolescents with major depressive disorder . GSK - Clinical Study Register (http://www.gsk-clinicalstudyregister.com) 2010. x-wiley/crsRef/18709859
42. Simeon JG, Dinicola VF, Ferguson HB, Copping W. Adolescent depression: a placebo controlled fluoxetine treatment study and follow-up. Progress in Neuro-Psychopharmacology and Biological Psychiatry 1990;14:791-5. x-wiley/crsRef/18709861
43. Emslie G, Kratochvil C, Vitiello B, Silva S, Mayes T, McNulty S et al, The Columbia Classification Team, The TADS Team. Treatment for Adolescents With Depression Study (TADS): safety results. Journal of the American Academy of Child Adolescent Psychiatry 2006;45(12):1440-55. x-wiley/crsRef/18709863
44. March J, Silva S, Petrycki S, Curry J, Wells K, Fairbank J et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents with Depression Study (TADS) randomized controlled trial. JAMA 2004;292:807-20. x-wiley/crsRef/18709864
45. Treatment for Adolescents with Depression Study (TADS) Team. Treatment for Adolescents with Depression Study (TADS): rationale, design, and methods. Journal of the American Academy of Child and Adolescent Psychiatry 2003;42:531-42. x-wiley/crsRef/18709865
46. Vitiello B, Silva S, Rohde P, Kratochvil C, Kennard B, Reinecke M et al. Suicidal events in the Treatment for Adolescents with Depression Study (TADS). Journal of Clinical Psychiatry 2009;70(5):741–7. x-wiley/crsRef/18709866
47. Medicines and Healthcare products Regulatory Agency (MHRA). Citalopram Study 2 ID#94404. http://medicines.mhra.gov.uk (accessed 20 June 2004). x-wiley/crsRef/18709868
48. von Knorring A, Olsson GI, Thomson PH, Lemming OM, Hulten A. A randomized, double blind, placebo controlled study of citalopram in adolescents with major depressive disorder. Journal of Clinical Psychopharmacology 2006;26(3):311-5. x-wiley/crsRef/18709869
49. Forest Laboratories. A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of citalopram in children and adolescent outpatients diagnosed with major depressive disorders (MDD) [CIT-MD-18]. Forest Clinical Trial Registry (http://www.forestclinicaltrials.com/CTR/CTRController/CTRViewPdf?_file_id=scsr/SCSR_CIT-MD-18final.pdf) 2005 (accessed 24 November 2011). x-wiley/crsRef/18709871
50. Medicines and Healthcare products Regulatory Agency (MHRA). Citalopram Study 1 ID# CIT-MD-18. http://medicines.mhra.gov.uk (accessed 20 June 2004). x-wiley/crsRef/18709872
51. Wagner KD, Robb AS, Findling R, Tiseo P. Citalopram is effective in the treatment of major depressive disorder in children and adolescents: results of a placebo-controlled trial. International Journal of Neuropsychopharmacology 2002;5(Suppl 1):161. x-wiley/crsRef/18709873
52. Wagner KD, Robb AS, Findling RL, Jin J, Gutierrez MM, Heydorn WE. A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents. American Journal of Psychiatry 2004;161:1079-83. x-wiley/crsRef/18709874
53. Wagner KD, Robb AS, Findling RL, Jin J, Tiseo PJ. Efficacy of citalopram in the treatment of MDD in children and adolescents [Abstract NR328]. Proceedings of the 155th Annual Meeting of the American Psychiatric Association: New Research Program and Abstracts; 2002 May 18-23; Philadelpheia, PA, USA 2002:90. x-wiley/crsRef/18709875
54. Forest Laboratories Ltd. Forest announces results of recently completed Lexapro pediatric depression clinical trial. http://www.healthyplace.com/Communities/Depression/news/children_antidepressants_lexapro_2.asp OR http://www.frx.com/ (accessed October 2004). x-wiley/crsRef/18709877
55. Wagner KD, Jonas J, Findling RL, Ventura D, Saikali K. A double-blind, randomized, placebo-controlled trial of escitalopram in the treatment of pediatric depression. Journal of the American Academy of Child and Adolescent Psychiatry 2006;45(3):280-8. x-wiley/crsRef/18709878
56. Pfizer Pharmaceuticals Inc. Study A050100. A multicenter 10-week randomized double-blind placebo-controlled flexible dose outpatient study of sertraline in children and adolescents with major depressive disorder. http://www.clinicalstudyresults.org/documents/company-study_98_0.pdf 2004 (accessed 24 November 2011). x-wiley/crsRef/18709880
57. Medicines and Healthcare products Regulatory Agency (MHRA). Sertraline Study 1 ID#1001. http://medicines.mhra.gov.uk (accessed 20 June 2004). x-wiley/crsRef/18709882
58. Medicines and Healthcare products Regulatory Agency (MHRA). Sertraline Study 2 ID # 1017. http://medicines.mhra.gov.uk (accessed 20 June 2004). x-wiley/crsRef/18709883
59. Wagner KD, Ambrosini P, Rynn M, Wohlberg C, Yang R, Greenbaum MS et al. Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder. JAMA 2003;290(8):1033-41. x-wiley/crsRef/18709884
60. Wagner KD, Wohlberg C. Efficacy and safety of sertraline for treatment of pediatric major depressive disorder [Abstract NR327]. In: 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, PA. 2002. x-wiley/crsRef/18709885
61. Wagner KD, Wohlberg CJ, Yang R. "Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder": Reply. JAMA 2004;291(1):42. x-wiley/crsRef/18709886
62. Pfizer Pharmaceuticals Inc. Study A0501017A. Multicenter 10-week randomized double-blind placebo-controlled flexible dose outpatient study of sertraline in children and adolescents with major depressive disorder. http://www.clinicalstudyresults.org/documents/company-study_1981_0.pdf 2004 (accessed 24 November 2011). x-wiley/crsRef/18709888
63. Braconnier A, Coent R, Cohen D. Paroxetine versus clomipramine in adolescents with severe major depression: a double blind, randomized, multicentre trial. Journal of the American Academy of Child and Adolescent Psychiatry 2003;42(1):22-9. x-wiley/crsRef/18709890
64. Cornelius JR, Bukstein OG, Wood DS, Kirisci L, Douaihy A, Clark DB. Double-blind placebo-controlled trial of fluoxetine in adolescents with comorbid major depression and an alcohol use disorder. Addictive Behaviors 2009;34(10):905-9. x-wiley/crsRef/18709892
65. Cornelius JR, Clark DB, Bukstein OG, Salloum IM, Matta J, Wood DS. Alcohol use but not cannabis use reported to contribute to depression in treatment trial of comorbid adolescents. In: Proceedings of the 68th Annual Scientific Meeting of the College on Problems of Drug Dependence; June 17-22 2006. Scottsdale, Arizona, USA, 2006. x-wiley/crsRef/18709893
66. Cornelius JR, Bukstein OG, Douaihy AB, Clark DB, Chung TA, Daley DC et al. Double-blind fluoxetine trial in comorbid MDD-CUD youth and young adults. Drug and Alcohol Dependence 2010;112(1-2):39-45. x-wiley/crsRef/18709895
67. Cornelius JR, Clark DB, Bukstein OG, Salloum IM, Matta J, Wood DS. Alcohol use but not cannabis use reported to contribute to depression in treatment trial of comorbid adolescents. In: Proceedings of the 68th Annual Scientific Meeting of the College on Problems of Drug Dependence; June 17-22. Scottsdale, Arizona, USA, 2006. x-wiley/crsRef/18709896
68. Cosgrove PVF. Fluvoxamine in the treatment of depressive illness in children and adolescents. Journal of Psychopharmacology 1994;8(2):118-23. x-wiley/crsRef/18709898
69. Findling RL, Pagano ME, McNamara NK, Stansbrey RJ, Faber JE, Lingler J et al. The short-term safety and efficacy of fluoxetine in depressed adolescents with alcohol and cannabis use disorders: a pilot randomized placebo-controlled trial. Child and Adolescent Psychiatry and Mental Health 2009;3(1):11. x-wiley/crsRef/18709900
70. Mandoki MW, Tappia MR, Tapia MA, Sumner GS, Parker JL. Veanlafaxine in the treatment of children and adolescents with major depression. Psychopharmacology Bulletin 1997;33(1):149-54. x-wiley/crsRef/18709902
71. National Institute of Mental Health. Fluoxetine for the treatment of major depression in youth with bipolar disorder [Study numbers N01-MH-70008A; N01-MH-70008]. http://www.clinicaltrials.gov/ct2/show/NCT00005015 2000 (accessed 24 November 2011). x-wiley/crsRef/18709904
72. Riggs PD, Lohman M, Davies R, Mikulich-Gilbertson S, Laudenslager M, Klein C et al. Randomized controlled trial of fluoxetine/placebo and cognitive behavioral treatments in depressed adolescents with substance use disorders. In: Proceedings of the 67th Annual Scientific Meeting of the College on Problems of Drug Dependence; June 19-23 2005. Orlando, Florida, USA, 2005. x-wiley/crsRef/18709906
73. Riggs PD, Mikulich-Gilbertson SK, Davies RD, Lohman M, Klein C, Stover SK. A randomized controlled trial of fluoxetine and cognitive behavioral therapy in adolescents with major depression, behavior problems, and substance use disorders. Archives of Pediatrics and Adolescent Medicine 2007;161(11):1026-34. x-wiley/crsRef/18709907
74. Thurstone C, Riggs PD, Orton HD, Libby AM. Fluoxetine for cannabis withdrawal in depressed adolescents. In: Proceedings of the 67th Annual Scientific Meeting of the College on Problems of Drug Dependence; June 19-23 2005. Orlando, Florida, USA, 2005. x-wiley/crsRef/18709908
75. Chabrol H, Peresson G. Pulse clomipramine for depressed adolescents [letter]. American Journal of Psychiatry 1998;155(7):995. x-wiley/crsRef/18709910
76. Sallee FR, Vrindavanam NS, Deas-Nesmith D, Carson SW, Sethuraman G. Pulse intravenous clomipramine for depressed adolescents: double-blind, controlled trial. American Journal of Psychiatry 1997;154(5):668-73. x-wiley/crsRef/18709911
77. Sallee FR. Dr. Sallee replies [letter]. American Journal of Psychiatry 1998;155(7):995. x-wiley/crsRef/18709912
78. Tashakori A, Arabgol F, Panaghi L, Davari R. The effect of reboxetine in the treatment of depression in children and adolescents. Tehran University Medical Journal 2007;65(8):40-8. x-wiley/crsRef/18709914
79. Wohlfarth T, Boer F, van den Brink W. Withdrawal of attention rather than pharmacological treatment affects suicide rates in depressed children and adolescents. American Journal of Psychiatry 2007;164(12):1908-10. x-wiley/crsRef/18709916
80. Eli Lilly. A double-blind, efficacy and safety study of duloxetine versus placebo in the treatment of children and adolescents with major depressive disorder. http://www.clinicaltrials.gov/ct2/show/NCT00849693 2009 (accessed 24 November 2011). x-wiley/crsRef/18709918
81. Eli Lilly. A double-blind, efficacy and safety study of duloxetine versus placebo in the treatment of children and adolescents with major depressive disorder. http://www.clinicaltrials.gov/ct2/show/NCT00849901 2009 (accessed 24 Nov 2011). x-wiley/crsRef/18709920
82. Glod CA, Lynch A, Berkowitz C, Hennen J, Baldessarini RJ. Bupropion versus citalopram versus placebo in adolescents with major depression [Abstract NR484]. 157th Annual Meeting of the American Psychiatric Association; May 1-6 2004 2004. x-wiley/crsRef/18709922
83. Yamaguchi T. SME3110 (fluvoxamine maleate) in the treatment of depression/depressive state: a post-marketing clinical study in children and adolescents (8 through 18 years of age) - a double-blind, randomized, placebo-controlled study. http://www.clinicaltrials.gov/ct2/show/NCT00353028 2010 (accessed 24 November 2011). x-wiley/crsRef/18709924
84. American Academy of Child and Adolescent Psychiatry. Supplementary talking points for child and adolescent psychiatrists: regarding the FDA black box warning on the use of antidepressants for pediatric patients. http://www.aacap.org/press_release/2004/1101.htm 31 October 2004.
85. Adolescent Health Research Group. A health profile of New Zealand youth who attend secondary school. New Zealand Medical Journal 2003;116(1171):3-12.
86. Altman DG, Royston P. The cost of dichotomising continuous variables. BMJ 2006;332(7549):1080.
87. Andrews JA, Lewinsohn PM. Suicide attempts among older adolescents: prevalence and co-occurance with psychiatric disorder. Journal of the American Academy of Child and Adolescent Psychiatry 1992;31(4):655-62.
88. Angold A. Childhood and adolescent depression II: Research in clinical populations. British Journal of Psychiatry 1988;153:476-92.
89. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Revised 4th edition. Washington, DC: American Psychiatric Association, 2000.
90. Asarnow JR. Suicidal ideation and attempts during middle childhood: associations with perceived family stress and depression among child psychiatric inpatients. Journal of Clinical Child Psychiatry 1992;21(1):35-40.
91. Axelson DA, Birmaher B. Relation between anxiety and depressive disorders in childhood and adolescence. Depression and Anxiety 2001;14(2):67-78.
92. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Archives of General Psychiatry 1961;4:561-71.
93. Birmaher B, Ryan ND, Williamson DE, Brent DA, Kaufman J, Dahl RE et al. Childhood and adolescent depression: a review of the past 10 years: Part 1. Journal of the American Academy of Child and Adolescent Psychiatry 1996;35(11):1427-39.
94. Brent DA, Kalas R, Edelbrock C, Costello AJ, Dulcan MK, Conover N. Psychopathology and its relationship to suicidal ideation in childhood and adolescence. Journal of the American Academy of Child and Adolescent Psychiatry 1986;25(5):666-73.
95. Brent DA, Perper JA, Moritz G, Allman C, Friend A, Roth C et al. Psychiatric risk factors for adolescent suicide: a case control study. Journal of the American Academy of Child and Adolescent Psychiatry 1993;32(3):521-9.
96. Brent DA, Birmaher B. Adolescent depression. New England Journal of Medicine 2002;347(9):667-71.
97. Brent. Antidepressants and pediatric depression - the risk of doing nothing. New England Journal of Medicine 2004;351(16):1598-601.
98. Bridge JA, Iyengar S, Salary CB, Barbe RP, Birmaher B, Pincus HA et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA 2007;297:1683-96.
99. Brooks SJ, Kutcher S. Diagnosis and measurement of depression: a review of commonly utilized instruments. Journal of Child and Adolescent Psychopharmacology 2001;11(4):341-76.
100. Carlson GA, Kashani JH. Phenomenology of major depression from childhood through adulthood: analysis of three studies. American Journal of Psychiatry 1988;145(10):1222-5.
101. Castren E. Is mood chemistry? Nature Reviews Neuroscience 2005;6(3):241-6.
102. Chambers WJ, Puig-Antich J, Hirsch M, Paez P, Ambrosini PJ, Tabrizi MA et al. The assessment of affective disorders in children and adolescents by semi-structured interview: test-retest reliability of the Schedule for Affective Disorders and Schizophrenia for school-age children. Present episode version. Archives of General Psychiatry 1985;42:696-702.
103. Cheung AH, Emslie GJ, Mayes TL. Review of the efficacy and safety of antidepressants in youth depression. Journal of Child Psychology and Psychiatry 2005;46(7):735-54.
104. Churchill R, Caldwell D, McGuire H, Barbui C, Cipriani A, Furukawa TA et al. Reboxetine versus other antidepressive agents for depression. Cochrane Database of Systematic Reviews 2010, Issue 6. Art. No: CD007852. [DOI: 10.1002/14651858.CD007852]
105. Cipriani A, Brambilla P, Furukawa T, Geddes J, Gregis M, Hotopf M et al. Fluoxetine versus other types of pharmacotherapy for depression. Cochrane Database of Systematic Reviews 2005, Issue 5. Art. No: CD004185. [DOI: 10.1002/14651858.CD004185.pub2]
106. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JPT, Churchill R et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. The Lancet 2009;373:746-58.
107. Cipriani A, Furukawa TA, Veronese A, Watanabe N, Churchill R, McGuire H et al. Paroxetine versus other anti-depressive agents for depression. Cochrane Database of Systematic Reviews 2009, Issue 3. Art. No: CD006531. [DOI: 10.1002/14651858.CD006531]
108. Cipriani A, Signoretti A, Furukawa TA, Churchill R, Tomelleri S, Omori IM et al. Venlafaxine versus other anti-depressive agents for depression. Cochrane Database of Systematic Reviews 2009, Issue 3. Art. No: CD006530. [DOI: 10.1002/14651858.CD006530]
109. Cipriani A, Santilli C, Furukawa TA, Signoretti A, Nakagawa A, McGuire H et al. Escitalopram versus other antidepressive agents for depression. Cochrane Database of Systematic Reviews 2009, Issue 2. Art. No: CD006532. [DOI: 10.1002/14651858.CD006532.pub2]
110. Cipriani A, La Ferla T, Furukawa TA, Signoretti A, Nakagawa A, Churchill R et al. Sertraline versus other antidepressive agents for depression. Cochrane Database of Systematic Reviews 2010, Issue 4. Art. No: CD006117. [DOI: 10.1002/14651858.CD006117.pub4]
111. Cohen D, Gerardin P, Mazet P, Purper-Ouakil D, Flament MF. Pharmacological treatment of adolescent major depression. Journal of Child and Adolescent Psychopharmacology 2004;14(1):19-31.
112. Cooper GL. The safety of fluoxetine - an update. British Journal of Psychiatry. Supplement 1988;3:77-86.
113. Costello JE, Erkanli A, Angold A. Is there an epidemic of child or adolescent depression. Journal of Child Psychology and Psychiatry 2006;47(12):1263-71.
114. Committee on Safety of Medicines (CSM). Report of the CSM expert working group on the safety of selective serotonin reuptake inhibitors antidepressants. http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/safetymessages/SSRIfinal.pdf 2004.
115. Cuijpers P, Dekker J. Psychological treatment of depression; a systematic review of meta-analyses [Psychologische behandeling van depressie; een systematisch overzicht van meta-analysen]. Nederlands Tijdschrift Voor Geneeskunde 2005;149:1892-7.
116. De Leo D. Why are we not getting any closer to preventing suicide? British Journal of Psychiatry 2002;181:372-4.
117. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7:177-88.
118. Dubicka B, Hadley S, Roberts C. Suicidal behaviour in youths diagnosed with depression treated with new-generation antidepressants. British Journal of Psychiatry 2006;189:393-98.
119. Dubitsky GM. Review and Evaluation of Clinical Data: Placebo-Controlled Antidepressant Studies In Pediatric Patients. Medicines and Healthcare Products Regulatory Agency 6 August 2004.
120. Dunlop BW, Vaughan CL. Survey of investigators opinions on the acceptability of interactions with patients participating in clinical trials. Journal of Clinical Psychopharmacology 2010;30(3):323-7.
121. Ebmeier KP, Donaghey C, Steele JD. Recent developments and current controversies in depression. Lancet 2006;367:153-67.
122. Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
123. European Medicines Agency. European Medicines Agency finalises review of antidepressants in children and adolescents. http://www.emea.eu.int/pdfs/human/press/pr/12891805en.pdf 25 April 2005.
124. Esposito CL, Clum GA. Psychiatric symptoms and their relationship to suicidal ideation in a high risk adolescent community sample. Journal of the American Academy of Child and Adolescent Psychiatry 2002;41(1):44-51.
125. Essau CF, Petermann F, Reynolds WM. In:Essau FPCA (Ed). Depressive Disorders in Children and Adolescents: Epidemiology, Risk Factors and Treatment. USA: Jason Aronson Inc, 1999.
126. FDA Public Health Advisory. Suicidality in children and adolescents being treated with antidepressant medications. http://www.fda.gov/cder/drug/antidepressants/SSRIPHA200410.htm 15 October 2004.
127. Findling R, Greenhill L. Message to AACAP members. President of the American Academy of Child and Adolescent Psychiatrists 2004.
128. Fleming JE, Boyle MH, Offord DR. The outcome of adolescent depression in the Ontario Child Health Study Follow-up. Journal of the American Academy of Child and Adolescent Psychiatry 1993;32(1):28-33.
129. Fombonne E, Wostear G, Cooper V, Harrington R, Rutter M. The Maudsley long-term follow-up of child and adolescent depression: I. Psychiatric outcomes in adulthood. British Journal of Psychiatry 2001;179:210-7.
130. Fombonne E, Wostear G, Cooper V, Harrington R, Rutter M. The Maudsley long-term follow-up of child and adolescent depression. 2. Suicidality, criminality and social dysfunction in adulthood. British Journal of Psychiatry 2001;179:218-23.
131. Friedman RA, Leon AC. Expanding the black box - depression, antidepressants, and the risk of suicide. New England Journal of Medicine 7 May 2007 [Epub ahead of print].
132. Garrison CZ, Waller JL, Cuffe SP, McKeown RE, Addy CL, Jackson KL. Incidence of major depressive disorder and dysthymia in young adolescents. Journal of the American Academy of Child and Adolescent Psychiatry 1997;36(4):458-65.
133. Gibbons RD, Brown CH, Hur K, Marcus SM, Bhaumik DK, Erkens JA et al. Early evidence on the effects of regulators’ suicidality warnings on SSRI prescriptions and suicide in children and adolescents. American Journal of Psychiatry 2007;164(9):1356–63.
134. Gloaguen V, Cottraux J, Cucherat M, Blackburn I-M. A meta-analysis of the effects of cognitive therapy in depressed patients. Journal of Affective Disorders 1998;49:59-72.
135. Goodyer IM, Wilkinson P, Dubicka B, Kelvin R. Forum: The use of selective serotonin reuptake inhibitors in depressed children and adolescents: commentary on the meta-analysis of Hetrick et al. Current Opinion in Psychiatry 2010;23:58-61.
136. Grunbaum J, Kann L, Kinchen SA, Williams B, Ross JG, Lowry R et al. Morbidity and mortality weekly report. Centres for Disease Control surveillance summaries. Youth Risk Behaviour Surveillance 2002.
137. Guaiana G, Gupta S, Chiodo D, Davies SJC. Agomelatine versus other antidepressive agents for major depression. Cochrane Database of Systematic Reviews 2010, Issue 11. Art. No: CD008851. [DOI: 10.1002/14651858.CD008851]
138. Gunnell D, Ashby D. Antidepressants and suicide: what is the balance of benefit and harm. BMJ 2004;329(7456):34-8.
139. Guy W. ECDEU Assessment Manual for Psychopharmacology. 2nd edition. Washington, DC: US Government Printing Office, 1976.
140. Hall WD. How have the SSRI antidepressants affected suicide risk? The Lancet 2006;367:1959-62.
141. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry 1960;23:56-62.
142. Hammad TA. Relationship between psychotropic drugs and pediatric suicidality. US Food and Drug Administration (FDA) 16 August 2004.
143. Hammad TA, Laugren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Archives of General Psychiatry 2006;63:332-9.
144. Harbord RM, Egger M, Sterne JA. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints. Statistics in Medicine 2006;25(20):3443-57.
145. Harbord RM, Harris RJ, Sterne JAC. Updated tests for small-study effects in meta-analyses. Stata Journal 2009;9(2):197-210.
146. Harrington R, Fudge H, Rutter M, Pickles A, Hill J. Adult outcomes of childhood and adolescent depression. I. Psychiatric status. Archives of General Psychiatry 1990;47(5):465-73.
147. Harrington R, Dubicka B. Natural history of mood disorders in children and adolescents. In: Goodyear IM, editors(s). The Depressed Child and Adolescent. Cambridge Child and Adolescent Psychiatry series. Cambridge: Cambridge University Press, 2001:311–43.
148. Hazell P, O'Connell D, Heathcote D, Henry D. Tricyclic drugs for depression in children and adolescents. Cochrane Database of Systematic Reviews 2002, Issue 2. Art. No: CD002317. [DOI: 10.1002/14651858.CD002317]
149. Healy D. The Anti-Depressant Era. Massachusetts: Harvard University Press, 1997.
150. Healy D. Lines of evidence on the risks of suicide with selective serotonin reuptake inhibitors. Psychotherapy and Psychosomatics 2003;72(2):71-9.
151. Healy D. Are selective serotonin reuptake inhibitors a risk factor for adolescent suicide? Canadian Journal of Psychiatry 2009;54(2):69-71.
152. Hetrick SE, Merry SN, McKenzie JE, Proctor M, Simmons M. Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents. Cochrane Database of Systematic Reviews 2007, Issue 3. Art. No: CD004851. [DOI: 10.1002/14651858.CD004851.pub2]
153. Hetrick SE, McKenzie JE, Merry SN. The use of SSRIs in children and adolescents. Current Opinion in Psychiatry 2010;23:53-7.
154. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
155. Higgins JP, White IR, Wood AM. Imputation methods for missing outcome data in meta-analysis of clinical trials. Clinical Trials 2008;5(3):225-39.
156. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009. Available from www.cochrane-handbook.org.
157. Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ 1999;319:670-4.
158. Imperadore G, Cipriani A, Signoretti A, Furukawa TA, Watanabe N, Churchill R et al. Citalopram versus other anti-depressive agents for depression. Cochrane Database of Systematic Reviews 2009, Issue 3. Art. No: CD006534. [DOI: 10.1002/14651858.CD006534]
159. Ioannidis JP. Effectiveness of antidepressants: an evidence myth constructed from a thousand randomized trials? Philosophy Ethics and Humanities in Medicine 2008;3:14.
160. Isacsson G, Rich CL, Jureidini J, Raven M. The increased use of antidepressants has contributed to the worldwide reduction in suicide rates. British Journal of Psychiatry 2010;196:429-33.
161. Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviours. JAMA 2004;292(3):338-43.
162. Julious SA. Issues with number needed to treat. Statistics in Medicine 2005;24(20):3233-5.
163. Jureidini J, Tonkin A. Paroxetine in major depression (letter). Journal of the American Academy of Child and Adolescent Psychiatry 2003;42(5):514.
164. Jureidini JN, Doecke CJ, Mansfield PR, Haby MM, Menkes DB, Tonkin AL. Efficacy and safety of antidepressants for children and adolescents. BMJ 2004;328:879-83.
165. Kaufman J, Martin A, King RA, Charney D. Are child-, adolescent-, and adult-onset depression one and the same disorder? Biological Psychiatry 2001;49:980-1001.
166. Keller MB, Ryan ND, Strober M, Weller EB, McCafferty JP, Hagino OR et al. Paroxetine in major depression [reply to Jureidini]. Journal of the American Academy of Child and Adolescent Psychiatry 2003;42(5):514-5.
167. Kieser M, Rohmel J, Friede T. Power and sample size determination when assessing the clinical relevance of trial results by 'responder analyses'. Statistics in Medicine 2004;23(21):3287-305.
168. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Medicine 2008;5(2):e45.
169. Kovacs M, Feinberg TL, Crouse-Novak MA, Paulauskas SL, Finkelstein R. Depressive disorders in childhood I: A longitudinal prospective study of characteristics and recovery. Archives of General Psychiatry 1984;41(3):229-37.
170. Kovacs M, Gatsonis C, Paulauskas SL, Richards C. Depressive disorders in childhood: IV. A longitudinal study of comorbidity with and risk for anxiety disorders. Archives of General Psychiatry 1989;46(9):776-82.
171. Kovacs M. The Children's Depression Inventory. North Tonawanda, New York: Mental Health Systems, 1992.
172. Kovacs M, Goldston D, Gatsonis C. Suicidal behaviours in child onset depressive disorders: a longitudinal investigation. Journal of the American Academy of Child and Adolescent Psychiatry 1993;32(1):8-20.
173. Lenox RH, Frazer A. Mechanism of action of antidepressants and mood stabilizers. In: Neuropsychopharmacology: The Fifth Generation of Progress. American College of Neuropsychopharmacology:http://www.acnp.org/publications/neuro5thgeneration.aspx, 2008:1139-63.
174. Lewinsohn PM, Rohde P, Seeley JR. Adolescent suicidal ideation and attempts: prevalence, risk factors and clinical implications. Clinical Psychology: Science and Practice 1996;3:25-46.
175. Lewinsohn PM, Rohde P, Seeley JR. Major depressive disorder in older adolescents: prevalence, risk factors and clinical implications. Clinical Psychology Review 1998;18(7):765-94.
176. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003;326(7400):1167-70.
177. Libby AM, Brent DA, Morrato EH, Orton HD, Allen R, Valuck RJ. Decline in treatment of pediatric depression after FDA advisory on risk of suicidality with SSRIs. American Journal of Human Genetics 2007;164(6):884-91.
178. Marttunen M, Pelkonen M. Phenomenology of adolescent depression. Psychiatria Fennica 1998;29:29-39.
179. Masi G, Favilla L, Mucci M. Depressive disorder in children and adolescents. European Journal of Paediatric Neurology 1998;2:287-95.
180. McDermott B, Baigent M, Chanen A, Fraser L, Graetz B, Hayman N et al. beyondblue Expert Working Committee (2010) Clinical practice guidelines: Depression in adolescents and young adults. Melbourne: beyondblue: the National Depression Initiative, 2011.
181. Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. Journal of Clinical Epidemiology 2010;63(8):e1-37.
182. Moncrieff J, Churchill R, Drummond C, McGuire H. Development of a quality assessment instrument for trials of treatments for depression and neurosis. International Journal of Methods in Psychiatric Research 2001;10(3):126-33.
183. Moncrieff J, Wessely S, Hardy R. Active placebo versus antidepressants for depression. Cochrane Database of Systematic Reviews 2005, Issue 1. Art. No: CD003012. [DOI: 10.1002/14651858.CD003012.pub2]
184. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. British Journal of Psychiatry 1979;134:382-9.
185. Murray CJ, Lopez AD. The Global Burden of Disease. A comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Harvard School of Public Health. Cambridge, MA: Harvard University Press, 1996.
186. Myers K, Winters NC. Ten-year review of rating scales: II: scales for internalizing disorders. Journal of the American Academy of Child and Adolescent Psychiatry 2002;41(6):634-59.
187. Nakagawa A, Watanabe N, Omori IM, Barbui C, Cipriani A, McGuire H et al. Milnacipran versus other antidepressive agents for depression. Cochrane Database of Systematic Reviews 2009, Issue 3. Art. No: CD006529. [DOI: 10.1002/14651858.CD006529.pub2]
188. Newman TB. A black-box warning for antidepressants in children? New England Journal of Medicine 2004;351(16):1595-9.
189. National Health and Medical Research Council. Depression in Young People: Clinical Practice Guidelines. Canberra: Australian Publishing Services, 1997.
190. National Institute for Health and Clinical Excellence (NICE). Depression in Children and Young People: Identification and management in primary, community and secondary care. National Clinical Practice Guideline 28. Leicester: The British Psychological Society, 2005.
191. Nosè M, Cipriani A, Furukawa TA, Omori IM, Churchill R, McGuire H et al. Duloxetine versus other anti-depressive agents for depression. Cochrane Database of Systematic Reviews 2009, Issue 3. Art. No: CD006533. [DOI: 10.1002/14651858.CD006533]
192. Olfson M, Shaffer D, Marcus SC, Greenberg T. Relationship between antidepressant medication treatment and suicide in adolescents. Archives of General Psychiatry 2003;60:978-82.
193. Olfson M, Marcus SC, Shaffer D. Antidepressant drug therapy and suicide in severely depressed children and adults: a case-control study. Archives of General Psychiatry 2006;63(8):865-72.
194. Olver JS, Burrows GD, Norman TR. Third-generation antidepressants - do they offer advantages over the SSRIs? CNS Drugs 2001;15(12):941-54.
195. Omori I, Watanabe N, Nakagawa A, Cipriani A, Barbui C, McGuire C et al. Fluvoxamine versus other anti-depressive agents for depression. Cochrane Database of Systematic Reviews 2010, Issue 3. Art. No: CD006114. [DOI: 10.1002/14651858.CD006114.pub2]
196. Boston College Department of Economics, http://econpapers.repec.org/RePEc:boc:bocode:s449201 HETEROGI: Stata module to quantify heterogeneity in a meta-analysis, Statistical Software Components. Orsini N, Bottai M, Higgins J, Buchan I. Boston College Department of Economics, http://econpapers.repec.org/RePEc:boc:bocode:s449201, 2006.
197. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. Journal of Clinical Epidemiology 2008;61(10):991-6.
198. Petersen AC, Compas BE, Brooks-Gunn J, Stemmler M, Ey S, Grant KE. Depression in adolescence. American Psychologist 1993;48(2):155-68.
199. Petti T. Scales of potential use in the psychopharmacological treatment of depressed children and adolescents. Psychopharmacology Bulletin 1985;21(4):951-6.
200. Pine DS, Cohen P, Gurley D, Brook J, Ma Y. The risk for early-adulthood anxiety and depressive disorders in adolescents with anxiety and depressive disorders. Archives of General Psychiatry 1998;55:56-64.
201. Poznanski EO, Grossman JA, Buchsbaum Y, Banegas M, Freeman L, Gibbons R. Preliminary studies of the reliability and validity of the children's depression rating scale. Journal of the American Academy of Child and Adolescent Psychiatry 1984;23:191-7.
202. Poznanski EO, Mokros HB. Children's Depression Rating Scale Revised. Los Angeles, CA: WPS, 1996.
203. Rao U, Ryan ND, Birmaher B, Dahl RE, Williamson DE, Kaufman J et al. Unipolar depression in adolescence: clinical outcome in adulthood. Journal of the American Academy of Child and Adolescent Psychiatry 1995;34(5):566-78.
204. Reseland S, Le Noury J, Aldred G, Healy D. Contributions to national suicide rates: autopsies and antidepressants. Journal of Psychotherapy and Psychosomatics 2008;77:78-82.
205. Reynolds WM. Reynolds Adolescent Depression Scale. Odessa, FL: PsychologicalAssessment Resources, 1986.
206. Reynolds WM. Suicidal Ideation Questionnaire. Odessam FL: Psychological Assessment Resources, 1987.
207. Richmond TK, Rosen DS. The treatment of adolescent depression in the era of the black box warning. Current Opinion in Pediatrics 2005;17(4):466-72.
208. Rivas-Vazquez RA, Saffa-Biller D, Ruiz I, Blais MA, Rivas-Vaquez A. Current issues in anxiety and depression: comorbid, mixed, and subthreshold disorders. Professional Psychology: Research and Practice 2004;35(1):74-83.
209. Safer DJ, Zito JM. Do antidepressants reduce suicide rates? Public Health 2007;121(4):274–7.
210. Sawyer MG, Arney FM, Baghurst PA, Clark JJ, Graetz RJ, Kosky R et al. The mental health of young people in Australia: key findings from the child and adolescent component of the national survey of mental health and well-being. Australian and New Zealand Journal of Psychiatry 2001;35:806-14.
211. Schorre BEH, Vandvik IH. Global assessment of functioning in child and adolescent psychiatry. European Child and Adolescent Psychiatry 2004;13(5):273-86.
212. Schott G, Pachl H, Limbach U, Gundert-Remy U, Lieb K, Ludwig W. The financing of drug trials by pharmaceutical companies and its consequences. Deutsches Ärzteblatt International 2010;107(17):295–301.
213. Shaffer D, Gould MS, Brasic J, Ambrosini P, Fisher P, Bird H et al. A children's global assessment scale (CGAS). Archives of General Psychiatry 1985;40:1228-31.
214. Shaffer D, Gould MS, Fisher P, Trautman P, Moreau D, Kleinman MM et al. Psychiatric diagnosis in child and adolescent suicide. Archives of General Psychiatry 1996;53(4):338-48.
215. Scherer RW, Langenberg P, von Elm E. Full publication of results initially presented in abstracts. Cochrane Database of Systematic Reviews 2007, Issue 2. Art. No: MR000005. [DOI: 10.1002/14651858.MR000005.pub3]
216. Sigafoos AD, Feinstein CB, Damond M, Reiss D. The measurement of behavioral autonomy in adolescence: the autonomous functioning checklist. Adolescent Psychiatry 1988;15:432-62.
217. Simon GE. How can we know whether antidepressants increase suicide risk. American Journal of Psychiatry 2006;163(11):1861-3.
218. Simon GE, Savarino J, Operskalski B, Wang PS. Suicide risk during antidepressant treatment. American Journal of Psychiatry 2006;163(1):41-7.
219. Sismondo S. Pharmaceutical company funding and its consequences: a qualitative systematic review. Contemporary Clinical Trials 2008;29:109–13.
220. Sondergard L, Kvist K, Andersen PL, Kessing LV. Do antidepressants precipitate youth suicide? A nationwide pharmacoepidemiological study. European Child and Adolescent Psychiatry 2006;15:232-40.
221. Sterne JA, White IR, Carlin JB, Spratt M, Royston P, Kenward MG et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ 2009;338:b2393.
222. Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 2011;343:d4002.
223. Stone M, Laughren T, Jones ML, Levenson M, Holland PC, Hughes A et al. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to USUS Food and Drug Administration. BMJ 2009;339:b2880.
224. Tsapakis EM, Soldani F, Tondo L, Baldessarini RJ. Efficacy of antidepressants in juvenile depression: meta-analysis. British Journal of Psychiatry 2008;193:10-7.
225. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. New England Journal of Medicine 2008;358:252-60.
226. Valuck RJ, Libby AM, Sills MR, Giese AA, Allen RR. Antidepressant treatment and the risk of suicide attempt by adolescents with major depressive disorder. CNS Drugs 2004;18(15):1119-32.
227. van Praag HM, Kahn RS, Asnis GM, Wetzler S, Brown SL, Bleich A et al. Denosologization of biological psychiatry or the specificity of 5-HT disturbances in psychiatric disorders. Journal of Affective Disorders 1987;13:1-8.
228. Vitiello B, Zuvekas SH, Norquist GS. National estimates of antidepressant medication use among US children. Journal of the American Academy of Child and Adolescent Psychiatry 2006;45(3):271-9.
229. Wagner KD. Pharmacotherapy for major depression in children and adolescents. Progress in Neuro-psychopharmacology and Biological Psychiatry 2005;29:819-26.
230. Watanabe N, Omori IM, Nakagawa A, Cipriani A, Barbui C, Churchill R et al. Mirtazapine versus other antidepressive agents for depression. Cochrane Database of Systematic Reviews 2011, Issue 12. Art. No: CD006528. [DOI: 10.1002/14651858.CD006528.pub2]
231. Weissman MM, Wolk S, Goldstein RB, Moreau D, Adams P, Greenwald S et al. Depressed adolescents grown up. JAMA 1999;281:1707-13.
232. Weisz JR, McCarty CA, Valeri SM. Effects of psychotherapy for depression in children and adolescents: a meta-analysis. Psychological Bulletin 2006;132:132-49.
233. Weller EB, Weller RA. Treatment options in the management of adolescent depression. Journal of Affective Disorders 2000;61(Suppl):23-8.
234. Wetzler S, Asnis GM, Hyman RB, Virtue C, Zimmerman J, Rathus JH. Characteristic of suicidality among adolescents. Suicide and Life-Threatening Behaviour 1996;26(1):37-45.
235. Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 2004;363(9418):1341-5.
236. World Health Organization. ICD-10: International statistical classification of diseases and related health problems. 2nd edition. Vol. 3. Geneva, Switzwerland: World Health Organization, 2004.
237. Winters NC, Collett BR, Myers KM. Ten-year review of rating scales, VII: scales assessing functional impairment. Journal of the American Academy of Child and Adolescent Psychiatry 2005;44(4):309-38.
238. Wisloff T, Aalen OO, Kristiansen IS. Considerable variation in NNT - a study based on Monte Carlo simulations. Journal of Clinical Epidemiology 2011;64(4):444-50.